Biotech
Gilead to buy cancer biotech Tubulis in US$5 billion deal
After the deal closes, Tubulis will become a research arm within Gilead
Now back in the black, SGX-listed Trendlines doubles down on core bets
The group is concentrating on assets in its strongest portfolio companies, says CEO Haim Brosh
US$14.8 million in prepayments to vendors behind Mirxes’ missed 2025 results deadline; independent probe set up
The investigation committee will oversee a review of 14 transactions and ‘associated subsequent events’
Insider and institutional positioning for the week
[SINGAPORE] For the five trading sessions spanning Mar 13 to 19, institutions were net buyers of Singapore stocks, with net institutional inflow of S$365 million. This took the accumulated net inflow ...
Asia’s biotech moment: From regional strength to global impact
Policy reform, new models and cross-border platforms make the region a key driver of biopharma innovation
Human brain cells run new data centres in Singapore, Melbourne
AI is driving a surge in electricity demand, forcing governments and technology companies to search for more efficient computing systems
Nasdaq-listed biotech company Cytek boosts Singapore facility with US$3 million investment
The firm aims to use the site to spearhead growth in Asia-Pacific
AI-powered microalgae hub to anchor Life3 Biotech’s position in sustainable proteins
Facility slated for completion in the fourth quarter of 2026 will house AI-driven bioreactors and a new visitor centre
Singapore’s biotech strategy will benefit from collective, not competitive, thinking
Successful innovation requires a holistic risk-based approach beyond financial, infrastructure and manpower investments
Novartis strikes deal with UK biotech for up to US$1.7 billion
Novartis is on a deal spree this year, including the US$12 billion acquisition of Avidity Biosciences
